ReviewPrecision chemistry2025
Adipose Tissue-Derived Extracellular Vesicle MicroRNAs: Diagnostic Biomarkers for the Pathophysiology Associated with Obesity.
Review in Precision chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MicroRNAs in Obesity, Insulin Resistance, and Type 2 Diabetes: Mechanistic Insights and Translational Perspectives.International journal of molecular sciences · 2026Review
- Exercise-conditioned extracellular vesicles in Alzheimer's disease: a multi-organ signaling network linking peripheral adaptation to brain pathology.Frontiers in immunology · 2026Review
- Precision Chemistry in Precision Diagnostics.Precision chemistry · 2025Article
- Extracellular vesicles in bone aging: therapeutic strategies and applications.Extracellular vesicles and circulating nucleic acids · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Obesity is a global health problem that increases the risk of type 2 diabetes, cardiovascular diseases, fatty liver disease, and cancer. The pathological outcomes of obesity and the responses to weight loss interventions vary significantly among individuals. The use of noninvasive biomarkers is critical for the early risk prediction of diseases associated with obesity and monitoring disease progression. MicroRNAs (miRNAs) are small noncoding RNAs that play pivotal roles in biological processes of adipose development, inflammation, and function. Dysregulation of numerous miRNAs has been implicated in the pathogenesis of obesity and associated diseases. In addition to exerting their function in the cytoplasm, mature miRNAs can be packaged into vesicles, released into extracellular space and body fluids, and act as paracrine and endocrine factors mediating intercellular and interorgan crosstalk. Encapsulation of miRNAs in extracellular vesicles (EVs) protects them from degradation and enhances their stability in body fluids. Moreover, the unique EV-miRNA signature reflects the state of the origin cells and is functionally related to disease pathology, supporting their potential as sensitive and specific biomarkers for clinical diagnostics. Adipose tissue is the main source of circulating EV-miRNAs in Obesity. Here we highlight the implication of adipose tissue-derived EV-miRNAs in metabolic disorders associated with obesity. Current understanding of the molecular mechanisms governing the sorting of miRNAs into EVs and recent advancements in relevant techniques are reviewed. In addition, limitations and future perspectives in this field are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.